Register of Blood Stem Cell Transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04263857

Acronym

REBB3M

Enrollment

5000

Registered

2020-02-11

Start date

2017-11-01

Completion date

2037-11-30

Last updated

2023-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancies

Keywords

autologous & allogenic blood stem cell transplantations

Brief summary

Detailed description

Documenting the success rate in terms of complication rate, disease response, survival rate, engraftment, and details of transplantation settings, for example donor and conditioning data, remission status before transplantation. It's a register of patients who have one or more autologous and / or allogenic blood stem cell transplants due to an existing indication for performing myeloablative / non-myeloablative high-dose chemotherapy. The inclusion occurs at our center during preparation for blood stem cell transplantation. The written consent will be obtained separately in the context of the information on blood stem cell transplantation. Participation is voluntary and consent can be revoked at any time. This involves no additional effort for the patient and has no influence on his treatment. It may be necessary in the course of contacting the patient at home, as long as the data is incomplete. This is also explicitly explained. A copy of the declaration of consent is given to the patient.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* signed IC * patients eligible for stem cell transplantation

Exclusion criteria

* unable to consent to study participation

Design outcomes

Primary

Measure	Time frame	Description
Register of stem cell transplantation	approximately over 20 years	Recording of all stem cell transplantations over many years

Secondary

Measure	Time frame	Description
Register of toxicities	approximately over 20 years	Recording of toxicities occured during and after SCT according to GvHD Score Standards and blood and bone marrow samples, and Imaging (CT Scans)
Register of complications	approximately over 20 years	Recording of complications occurred during and after SCT in Terms of infectious complications and occurance of GvHD (according to GvHD Score and Imaging and clinical assessment)
Register of morbidities	approximately over 20 years	—
Register of survivals	approximately over 20 years	Recording of survival Status, Assessment of Remission Status by bone marrow and blood diagnostics, clinical follow up

Countries

Germany

Contacts

Primary ContactMareike Verbeek, MD

mareike.verbeek@tum.de+49 89 4140

Outcome results